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Abstract
Background: Endometrial carcinoma (EC) is the most common malignancy of the female genital tract. Gene
alterations and overexpression of various oncogenes are important in tumor development. The human HER 2 neu
(c-erbB-2) gene product is a transmembrane receptor with an intracellular tyrosine kinase that plays an important
role in coordinating the endometrial growth factor receptor signaling network. The aim of this study was to
investigate the expression of c-erbB-2 in endometrial cancer, to study its correlation to established prognostic
parameters and estrogen receptor (ER) and progesterone receptor (PR) status.
Methods: Immunohistochemical (IHC) analyses of ER, PR and c-erbB-2 were performed in 72 EC cases.
Results: We detected a positive staining with c erbB 2 in 18.1% of the cases and determined a statistically
significant relation between c-erbB-2 and PR. We could not find a statistically significant relation between c-erbB-2
staining and ER. There was not a statistically significant difference between c-erbB-2 and histological grade. The
highest level of c-erbB-2 was found in grade 2 cases. There was not any statistically significant relation between
c-erbB-2 and menstrual status, myometrial invasion, lymph node status, stage and survival.
Conclusions: Although our study provides additional evidence of the potential prognostic role of c-erbB-2, further
prospective and controlled studies are required to validate their clinical usefulness.
Background
EC is the most common malignancy of the female geni-
tal tract in industrialized countries, and occurs predomi-
nantly after menopause [1-14].
Histological grade is strongly associated with prog-
nosis, stage, lymph-node metastasis and myometrial
invasion. Nonendometrioid carcinomas are considered
high-grade tumors and thus need not be graded. Grade
is one of the prognostic factors applied in clinical deci-
sions regarding treatment. The most frequently used
grading criteria are the ones of International Federation
of Gynecology and Obstetrics (FIGO) and the World
Health Organization (WHO), which include both archi-
tectural and nuclear features [1]. The presence of metas-
tases in the lymphatic or vascular spaces of the uterus
and lymphovascular space involvement is an important
prognostic factor for relapse of disease and poor survi-
val, and it is independent of histological grade or depth
of myometrial invasion [1].
Steroid hormones, especially estrogen, play an impor-
tant role in the pathogenesis of EC. It is postulated that
estrogen exposure unopposedb yp r o g e s t i n si n c r e a s e s
the risk of endometrial hyperplasia and cancer
[1,9,11,15]. Estrogen receptors (ERs) and progesterone
receptors (PRs) are generally decreased in EC compared
with endometrial hyperplasia and the loss of receptors is
a part of the carcinogenesis of the endometrium [9]. In
recent years, the molecular analysis of EC has identified
abnormalities in the expression, structure, or activity of
oncogene products which can contribute to the develop-
ment and maintenance of the malignant phenotype [3].
HER-2, also known as c-erbB-2, is a 185 kd trans-
membrane receptor protein encoded by HER-2/neu
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member of the epidermal growth factor receptor family
with tyrosine kinase activity together with HER-1, HER-
3, and HER-4. Epidermal growth factor (EGF) receptor
related with growth factors has a regulatory role, parti-
cularly by influencing the mitogenic activity
[2,4-7,12,13].
When c-erbB-2 is normally expressed, it leads to the
combination of a few copies of c-erbB-2 heterodimers
and the c-erbB-2-mediated signaling is weak, resulting
in a normal cell growth [2]. Overexpression of c-erbB-2
has been associated with a more agressive biological
behavior of human tumors including breast and ovarian
cancer, prostate, bladder, cervical cancer, and EC [2,5,6].
Overexpression of the c-erbB-2 oncogene occurs in
about 10% to 40% of EC and has been associated with
other adverse prognostic factors, including advanced
stage, higher grade and worsened overall survival
[1,7,16-20].
The aim of this study was to investigate the expression
of c-erbB-2 in endometrial cancer, to study its correla-
tion to established prognostic parameters and estrogen
receptor (ER) and progesterone receptor (PR) status.
Methods
The study was performed on 72 endometrial adenocarci-
noma cases diagnosed between 2004-2007 at Dr. Lutfi
Kirdar Training and Research Hospital Pathology Clinic.
The patients were allocated to two groups according to
their menstrual status as premenopausal and postmeno-
pausal. All the cases were hysterectomy specimens and
were diagnosed as endometrioid EC. Histological char-
acteristics were abstracted from the original pathology
reports. The hematoxylin-eosin-stained sections of the
hysterectomy specimens from all the patients were re-
evaluated by two of the authors (AEG, SHK) to confirm
the histologic type, grade, depth of myometrial invasion
and stage. The histological classification which was in
consistency with the classification of the WHO architec-
tural grading was based on thed e g r e eo fg l a n d u l a rd i f -
ferentiation in accordance with the FIGO guidelines.
The cases were categorized as well-differentiated grade
1 (G1), moderately differentiated grade 2 (G2), and
poorly differentiated grade 3 (G3) adenocarcinomas
according to the WHO criteria. Depth of myometrial
invasion was categorized as no myometrial invasion,
invasion within 1/2 thickness of the myometrium, and
invasion of >1/2 thickness of the myometrium. The
cases of which lymph node dissection was performed
were classified into two groups; with lymph node metas-
tasis and without lymph node metastasis. Staging was
performed according to the TNM and FIGO classifica-
tion. FIGO stage was ascertained from the surgical
pathology reports. The paraffin block that best
represented the tumor was selected for the immunohis-
tochemical examination. To collect the necessary infor-
mation about the patient’ss u r v i v a lw et r i e dt or e a c ha l l
of the cases and we were able to contact 44 patients by
phone through the information available in the oncology
clinic records, but we could not contact 28 patients.
Immunohistochemistry
Three μm sections obtained from the selected paraffin
blocks were taken on to adhesive-coated slides and kept
overnight in 37°C incubator. After deparaffinization, the
slides were passed from graded alcohols for 15 min and
rinsed in distilled water. The slides were then placed in
pH 6.0 citrate buffer for antigen retrieval process in
microwave oven for 20 min. Endogenous peroxidase
activity was blocked by 10 min. of incubation with 3%
hydrogen peroxide. To prevent nonspecific bindings,
blockage was done for 10 min. ([Dako], Cytomation
protein block serum-free, ref x0909, lot 10016138). The
primary antibodies used were as follows: polyclonal rab-
bit antihuman c-erbB-2 oncoprotein ([Dako] Cytoma-
tion EnVision A0485 affinity isolated/10 dilution 90
min.) monoclonal rabbit ER antibody (rabbit monoclo-
nal antihuman) ([Spring Bioscience], Code M3011, Lot.
70918, 1: 100 dilution, 90 min.), monoclonal mouse
antihuman PR antibody ([Dako] Cytomation EnVision
Clone PgR636, Lot. 00009021, 1:100 dilution 90 min.).
Secondary antibodies were used for 30 min. with pri-
mary antibody enhancer ([Spring Bioscience] cat: DPE-
125, Lot:70828) for 30 min. The slides were incubated
for 30 min. with polyvalent HRP polymer ([Spring
Bioscience] cat: DPE-125, Lot:70918). AEC chromogen
system was applied to slides for 15 min ([Spring
Bioscience] catalog: ASS-125 ready to use). Contrast
staining was done with Mayer’s hematoxylene and slides
were finally covered with water-based cover material.
For c-erbB-2, ER and PR, breast tissue, positivity of
which had been proven previously was used as a posi-
tive control. Immunoreactivity of c-erbB-2 was observed
in the cell membrane and was scored semiquantitatively
using the Food and Drug Administration (FDA)
approved scoring system as: 0, no immunostaining; 1+,
incomplete membranous immunostaining of <10% of
tumor cells; 2+, weak complete membranous immunos-
taining of >10% of tumor cells; 3+, strong complete
membranous staining of >10% of tumor cells. Scores of
0 or 1+ indicated a negative result, while scores of 2+
and 3+ were regarded as positive c-erbB-2 expression
[7]. ER and PR examinations were done based on the
percentage of the stained cells and the intensity of the
nuclear staining. The percentage of positive cells was
graded as follows: 1 = 0 to 25% of the nuclei stained; 2
= 26 to 75% of nuclei stained, 3 = more than 76% of
the nuclei stained. The staining intensity was scored as
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The sum of both of the parameters determined the IHC
score. Tumors were classified to three categories
depending on the IHC score. Category I corresponded
to a score of 2 and category II to a score of 3 or 4, and
category III to a score of 5 or 6. Category-I tumors
were considered as immunonegative, whereas category
II and III tumors were considered as immunopositive
[21]. The relationships between c-erbB-2, ER-PR status,
menstrual status, histological grade, myometrial invasion
depth, lymph node status, and stage were investigated.
Statistical Analysis
SPSS (Statistical Package for Social Sciences) for Win-
dows 15.0 software was used for the statistical analysis.
For the comparison of quantitative data, Chi-square and
crosstabulation tests were used. Results were analysed at
p < 0.05 significance and 95% confidence interval.
Results
The present study included 72 patients who had under-
gone surgery due to EC of the uterine corpus. Twenty
two patients (30.6%) were premenopausal, and 50
patients (69.4%) were postmenopausal. The mean age of
the patients was 58.3 years (range, 30-81). When classi-
fied according to grades, 25 patients (34.7%) were G1,
39 patients were (54.2%) G2, and 8 patients were
(11.1%) G3. Invasion depth was less than 1/2 in 41
(56.9%) patients, and more than 1/2 in 25 (34.7%)
patients. However, in 6 (8.3%) patients myometrial inva-
sion was not observed and tumors were limited to the
endometrium. There were 34 cases that lymph node dis-
section was done; in 4 (11.8%) cases lymph node metas-
tases were detected. There were 28 cases at stage I and
there was only one case at stage II. There were 5 cases
at stage III. We were able to collect the information of
49 patients; 44 of them survived but 5 of them died.
The follow-up period was at least 24 months. The char-
acteristics of the cases are given in detail on Table 1.
Among all 18.1% had positive staining with c-erbB-2
(Figure 1). C-erb-B2 was positive in 6 (27.3%) of the 22
premenopausal patients, and also positive in 7(14%) of
the 50 postmenopausal patients. C-erbB-2 positivity was
determined in 3 cases that were G1 (12%), 9 cases that
were G2 (23.1%), and one case that was G3 (12.5%). No
significant difference was determined (p > 0,05) between
the histological grades and the cases that had c-erbB-2
expression. The highest c-erbB-2 positivity was in grade
2 cases (23.1%). There were ten (24.4%) myometrial
invasion cases less than 1/2. Two (8%) myometrial inva-
sion cases which were more than 1/2 and 1 (16.7%) case
with no myometrial invasion had a positive reaction
with c-erbB-2. There was no statistically significant dif-
ference between the invasion depth and the cases with
c-erbB-2 expression. One case (25%) with lymph node
metastasis showed positive staining with c-erbB-2. Posi-
tive staining with c-erbB-2 was also detected in 2 cases
(6.7%) that lymph node metastases was not detected.
Immunoreactivity with c-erbB-2 was detected in 2 cases
in stage I (7.1%), there was only one case detected in
stage II and no staining with c-erbB-2 was observed in
this case. Immunoreactivity with c-erbB-2 was detected
i no n ec a s e( 2 0 % )i ns t a g eI I I .T h ep r o p o r t i o no ft h e
survived patients that were staining with cerb-B-2 was
(18.18%). There was not a statistically significant relation
with survival and cerb-B-2.
ER positivity was determined in 61 of the 72 cases
(84.7%) and PR positivity was determined in 59 of the
72 cases (81.9%) (Figure 2). The proportion of the posi-
tive staining between ER and grades (1-2-3) were 24
(96%), 33(84.6%) and 4(50%), respectively. The propor-
tion of the staining was observed but there was not a
statistically significant relation between ER and the
grades. PR expression was determined relatively high in
proportion among the G1 and G2 cases. In G3 cases PR
expression ratio was low and it was statistically signifi-
cant (p < 0.05). Positive staining was observed both in
ER and PR in 23 (82.14%) out of the 28 stage I cases.
There was only one case in stage II and positive staining
was observed both in ER and PR. All of the 5 cases in
stage III showed positive staining with ER but only 3 of
Table 1 Distribution of parameters
n %
Menstrual Status Premenopausal 22 30,6
Postmenopausal 50 69,4
Histological grade Grade 1 25 34,7
Grade 2 39 54,2
Grade 3 8 11,1
Invasion depth <1/2 41 56,9
>1/2 25 34,7
Limited to endometrium 6 8,3
Lymph-Node Status Missing (no lymph node) 38 52,8
Positive 4 5,6
Negative 30 41,7
I 28 82,4
Stage II 1 2,9
III 5 14,7
c-erbB-2 Positive 13 18,1
Negative 59 81,9
Estrogen Positive 61 84,7
Negative 11 15,3
Progesterone Positive 59 81,9
Negative 13 18,1
Survival Alive 44 89,7
Death 5 10,3
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any statistically significant relations between ER-stage-
survival and PR-stage-survival. Nine cases (14.8%) of all
with ER positivity and 8 (13.6%) of the cases with PR
positivity showed a positive staining with c-erbB-2 stain-
ing characteristics are summarized in Table 2, 3 and 4.
There was no statistically significant relation between
c-erbB-2 and ER (p > 0.05). There was a statistically
significant relation between c-erbB-2 and PR (p < 0.05).
C-erbB-2 expression was observed in a higher ratio in
PR negative cases compared with PR positive cases.
Discussion
C-erbB-2 protein overexpression and c-erbB-2 gene
amplification are frequently associated with a more
aggresive and chemoresistant disease in cancer patients
Figure 1 Positive reaction for c-erbB-2 in endometrial adenocarcinoma (IHC×400).
Figure 2 Strong immunoreactivity for PR in the endometrial adenocarcinoma (IHC×200).
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According to the results reported by Brys et al. the
erbB-1 and erbB-2 mRNA expression level was signifi-
cantly higher in malignant human endometrium com-
pared to benign tissue. Moreover, a significant
correlation between erbB-1 overexpression and tumor
differentiation was observed (p < 0.001). However,
protein expression did not correlate with any known
prognostic variables [4].
Kohlberger et al. found 21% HER-2/neu oncoprotein
expression and according to their study, clinical stage,
histologic stage, histologic grade and depth of invasion
did not correlate with c-erbB-2 oncoprotein expression
[20]. Therefore c-erbB-2 oncoprotein was observed in
all clinical stages and it did not seem to be a late
event in the natural history of EC. They also reported
that c-erbB-2 oncoprotein expression was associated
with poor overall survival (long-rank P-value 0.04)
[20]. Khalifa et al. reported that c-erbB-2 overexpres-
sion was significantly associated with depth of myome-
trial invasion [22]. Coronado et al. found that
prognostic value of the c-erbB-2 overexpression was
h i g h e ri ne a r l ys t a g e st h a ni na d v a n c e ds t a g e so fd i s -
ease. The authors commented that this might have
been related to the higher levels of overexpression
found in serous and G3 cancers [21].
We observed 18.1% positive staining with c-erbB-2 in
our study; and there wasn’t any expressive relation with
c-erbB-2 and respectively menstrual status, age or depth
of myometrial invasion. In our research, even though we
determined approximately the same ratio of c-erbB-2
positivity in G1 and G3 tumors, we found out that the
ratio of c-erbB-2 positivity was relatively high in G2
tumors. C-erbB-2 staining and grade did not show a sta-
tistically significant relation (p > 0.05). Most of the cases
were in G2 and the statistical results might be related
with the number of G2 cases and the insufficient num-
b e ro fG 3c a s e s .W ew e r ea b l et om a k e“staging” for 34
of the cases and most of them were at stage I. In our
study, cerbB-2 positivity was determined in stage I and
stage III tumors. There was only one case in stage II
and there was not any c-erbB-2 expression. Even though
we determined a relatively high proportion of c-erbB-2
expression in stage III tumors, there was not any
Table 2 c-erbB-2 score evaluations
c-erbB-2 score
Negative
n (%)
Positive
n (%)
P†
Menstrual Status Premenopausal 16 (72,7) 6 (27,3)
Postmenopausal 43 (86) 7 (14) 0,177
Histological
Grade
Grade 1 22 (88) 3 (12) 0,484
Grade 2 30 (76,9) 9 (23,1)
Grade 3 7 (87,5) 1 (12,5)
Invasion Depth <1/2 31 (75,6) 10
(24,4)
0,243
>1/2 23 (92) 2 (8)
Limited to
endometrium
5 (83,3) 1 (16,7)
Lymph Node
Status
Positive 3 (75) 1 (25) 0,615
Negative 28 (93,3) 2 (6,7)
Stage I 26 (92,9) 2 (7,1)
II 1 (100) 0 (0)
III 4 (80) 1 (20)
Estrogen Positive 52 (85,2) 9 (14,8) 0,086
Negative 7 (63,6) 4 (36,4)
Progesterone Positive 51 (86,4) 8 (13,6) 0,035
Negative 8 (61,5) 5 (38,5)
Survival Alive 36
(81,82)
8
(18,18)
0,215
Death 5 (100) 0 (0)
†: Chi square test. p < 0,05 significant; p > 0,005 insignificant
Table 3 The Relationship Between Estrogen with Grade,
Stage, Survival
Estrogen
Negative (n = 11)
n(%)
Positive(n = 61)
n(%)
P
Survival 1 (alive) 3(6,8) 41 (93,2) 0,592
2( death) 1(20,0) 4 (80,0)
Grade 1 1 (9,1) 25 (40,3) 0,006**
2 6 (54,5) 33 (53,2)
3 4 (36,4) 4 (6,5)
Stage I I5(17,9) 23(82,1) 0,543
II 0 (0) 1(100)
III 0 (0) 5 (100)
**Statistically insignificant: p value > 0,005
*Statistically significant p value < 0,05
Table 4 The Relationship Between Progesterone with
Grade, Stage, Survival
Progesterone
Negative (n = 13)
n(%)
Positive (n = 59)
n(%)
p
Grade 1 2 (17,8) 23 (82,2) 0,002**
2 6 (15,4) 33 (84,6)
3 5 (62,5) 3 (37,5)
Stage I 4 (14,8) 23 (85,2) 0,085
II 0 (0) 1 (100)
III 2 (40) 3 (60)
Survival 1 (alive) 5 (11,4) 39 (88,6) 0,076
2 (death) 2 (40) 3 (60)
**Statistically insignificant: p value > 0,005
*Statistically significant p value < 0,05
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cient number of stage III cases.
In the study by Grushko et al. HER-2 gene amplifica-
tion was detected in 44%. There was a significant asso-
ciation between the grade and HER-2 amplification
among nonserous tumors. Neither overexpression nor
amplification predicted overall survival after adjusting
for treatment and performance status [7]. Backe et al.
also showed that immunohistochemically detected
expression of c-erbB-2 was not a clinical prognostic fac-
tor in endometrial cancer [17].
In our study there was not a statistically significant
relation between survival and c-erb-B-2. This result
might be due to the insufficient number of followed-up
patients and the short time period.
There are studies revealing that c-erbB-2 is a poor
prognostic factor or it has no relation with prognosis.
Because of that the c-erbB-2 immunstaining is difficult
to use as a predictor for prognosis [18]. It is well-known
that anti c-erbB-2 antibodies have very variable sensitiv-
ity in formalin-fixed, paraffin-embedded tissue, and that
other technical issues are also critical [23]. The variabil-
ity in c-erbB-2 immunostaining results in the literature
is probably related both to a different mix of patients in
different series, and the wide variety of antibodies and
staining conditions used. However the number of cases
with c-erbB-2 overexpression is small, in both our series
and in the other series in the literature, limited the pre-
cision of the results.
It is well known that cytosolic ERs and PRs can be
identified in EC and a correlation between the contents
of ER and PR within individual lesions has been demon-
strated. Well differentiated tumors are more likely to be
ER and PR positive than poorly differentiated neo-
plasms. So, the presence of ER and PR in EC is sug-
gested to be inversely proportional to the nuclear grade
and FIGO stage of the lesion [10]. In a study, ER and
PR expression in EC was significantly associated with
both well-differatiated and early-stage ECs which were
positive for both ER and PR. (19). In the study by Bigsby
et al. c-erbB-2 oncogene protein, epidermal growth fac-
tor receptor, ER, and PR were examined immunohisto-
chemically in specimens of normal and neoplastic
endometrium. There was an inverse relationship
between overexpression of c-erbB-2 and PR in EC. On
the other hand, the overexpression of c-erbB-2 in EC
did not seem to be related to the loss of other differen-
tiated characteristics [24].
Berchuck et al. in their study reported that high
expression of c-erbB-2 was found in 27% of patients
with metastatic disease compared with 4% of patients
with disease confined to the uterus (p < 0.005). High
cerbB-2 expression also was associated with absence of
ER (p < 0.005) and with increased mortality from cancer
[25]. Benevolo et al. reported that c-erbB-2 expression
also influenced the patient outcome in the group with
tumors lacking PRs (p = 0.004). In multivariate analysis
PRs and c-erbB-2 overexpression emerged as indepen-
dent prognostic factors [3].
In our study, in low grade tumors the number of ER
and PR positive cases were relatively high. There was a
statistically significant relation between PR and the
grade. PR expression ratio decreased in high grade
tumors. C-erbB-2 staining and ER did not show a statis-
tically significant relation (p > 0.05). However, it is note-
worthy that, in ER negative cases, c-erbB-2 expression
was high. We found a statistically significant relation
between c-erbB-2 and PR (p < 0.05). There was an
inverse relationship between overexpression of c-erbB-2
and PR in EC. In PR negative cases, expression of
cerbB-2 was statistically significantly high. On the other
hand; there was not any statistically significant relation
between ER-stage-survival and PR-stage-survival. Even
though we couldn’t find any relation between these vari-
ables, we thought that absence of PR might be related
to the worse clinical process depending on literature.
Moreover, the absence of PR and c-erbB-2 expression in
EC, which is known as endocrine related neoplasm,
could be a reliable parameter in the selection of specific
hormonal treatment models.
Conclusions
As a result, our study showed that c-erbB-2 positivity did
not have a significant relation with menstrual status, his-
tologic grade, myometrial invasion, lymph node status,
stage, survival or ER status. It was found to be related
with only PR. However we believe that these results pro-
vide additional evidence of the potential prognostic role
of c-erbB-2, and it is worthwhile to investigate this mar-
ker with further prospective and controlled studies.
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